ChemComm

Accepted Manuscript

This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](http://www.rsc.org/Publishing/Journals/guidelines/AuthorGuidelines/JournalPolicy/accepted_manuscripts.asp).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](http://www.rsc.org/help/termsconditions.asp) and the Ethical quidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

www.rsc.org/chemcomm

Journal Name RSCPublishing

COMMUNICATION

Cite this: DOI: 10.1039/x0xx00000x

Received 00th January 2012, Accepted 00th January 2012

DOI: 10.1039/x0xx00000x

www.rsc.org/

Improved method for synthesis of cysteine modified hyaluronic acid for *in-situ* **hydrogel formation**

Xin Zhang,^{*a*} Pengcheng Sun,^{*a*} Lingzi Huangshan,^{*a*} Bi-Huang Hu^{**a*} and Phillip B. Messersmith**^b*

We developed a new strategy for the functionalization of hyaluronic acid by chemical modification of its C-6 hydroxyl groups through an ether bond to obtain a cysteine-hyaluronic acid conjugate. This conjugate is suitable to prepare injectable and *in situ* **formed hydrogels cross-linked by native chemical ligation and Michael addition under mild conditions.**

Hyaluronic acid (HA) is a non-sulfated anionic linear polysaccharide consisting of *β*-(1, 4) linked D-glucuronic acid-*β*-(1, 3)-*N*-acetyl-Dglucosamine disaccharide repeats. HA has a molecular weight ranging from 100 kDa to 8 MDa and is ubiquitous in the human body, especially in the synovia of joints, the corpus vitreum of the eyes and the dermis of the skin. 1 As an essential signalling biomacromolecule, HA is located in the extracellular matrix (ECM), at the cell surface and inside the cell, where it is involved in many cellular functions such as water homeostasis, cell migration, proliferation and adhesion.²

HA has a short half-life of only about 1 to 2 days in tissue, limiting its applications as a biocompatible, biodegradable and nonimmunogenic polymer.³ Chemical modification and cross-linking of HA has been used to achieve longer residence time in vivo while maintaining biocompatibility and viscoelastic properties of the naturally occurring biomolecule.⁴ Modified HA has been used in various physical forms – viscoelastic solutions, soft or stiff hydrogels, macroporous and fibrillar sponges, nanoparticulate fluids and flexible sheets.⁵ A wide range of biomedical applications utilizing HA derivatives have been developed, such as viscosupplementation, \degree cell differentiation,⁷ tissue sealants,⁸ tissue augmentation,⁹ ophthalmic surgery,¹⁰ engineering of bioactive surfaces,¹¹ drug delivery,¹² and minimally invasive in-situ formation of hydrogels under physiological conditions.¹³ Such applications are facilitated by modification

strategies that permit chemical functionalization while preserving the biological activity of HA.¹⁴

 Strategies for modification of HA often target the carboxylic acid of the glucuronic acid and primary hydroxyl groups of the biomacromolecule.¹⁵ The carboxyl groups have been commonly modified by amidation and esterification using carbodiimidemediated chemistry. However, derivatization of HA in this manner may form *N*-acylurea-type EDC adduct,¹⁶ which causes the resulting HA conjugate to be immunogenic. 17 Furthermore, the biological functions of HA are considered to be mediated through specific ionic interactions between HA carboxylates and cationic amino acids of the cell surface receptor CD44, and five or more HA disaccharide units in length have been shown to be necessary for optimal CD44 binding. $^{\rm 18}$

 Alternative HA modification strategies to target the hydroxyl groups of HA have employed divinyl sulfone, diglycidyl ether, glutaraldehyde, and ester linked glycidyl methacrylate, or methacrylic anhydride.^{4-5, 15a, 19} For the preparation of thiolated HA, a previous report described an HA derivatized with free thiol groups (HASH) through ether bond linkage by reaction of the hydroxyl groups of HA with ethylene sulphide.²⁰ Unfortunately, the reported HASH was unable to form cross-linked HA hydrogels via disulfide bonds, or through bivalent thiol-reactive cross-linkers, indicating that employing this strategy for HA gel formation was rather challenging.

 In the interest of developing cysteine derivatized HA (Cys-HA) for chemo-selective gel formation under mild conditions,²¹ here we report a new strategy for the preparation of Cys-HA useful for in-situ formation of hydrogels by native chemical ligation. The method preserves the free carboxylic acids by conjugating the cysteine through a stable ether linkage via the HA hydroxyl groups (Scheme 1). Starting with commercially available L-cysteine hydrochloride **1**, compound 3 was prepared in two steps,²² followed by activation of the

carboxylic acid with *N*-hydroxysuccinimide (HOSu) to afford the active ester **4**. Cystamine is an unstable liquid and is generally handled as the dihydrochloride salt, scarcely soluble in organic solvents. Therefore, compound **4** as an active ester can facilitate the reaction with cystamine dihydrochloride in aqueous solution to generate compound **5** without an extra step for the conversion of the salt to the free amine. Selective reduction of the disulfide of compound 5 with NaBH₄ yielded compound 6 with free thiol group,²³ a nucleophile that is highly reactive with epoxides under mild conditions. Addition of compound **6** to one epoxide group of 1,4-butanediol diglycidyl ether (BDDE) produced compound **7** containing an epoxide group, which was then used to modify HA at its alcohol groups through an ether bond linkage.

Scheme 1. Synthesis of Cys-HA conjugate 9.

 The hydroxyl groups in HA are nucleophiles, which can react with epoxides in a ring-opening process to form ether bonds at high pH conditions (usually above 11). However, we found that the reaction of the epoxide **7** with HA in alkaline solution (0.1 M NaOH solution) could not afford the expected modified HA, as indicated by the absence of the ¹HNMR signal of the Boc protecting group. A number of reaction conditions for this reaction, including mixtures of alkaline acetonitrile or THF as well as use of HA-TBA salt in DMSO after TBA salt conversion by ion exchange chromatography, were explored without success. Finally, we discovered that introduction of tetrabutylammonium hydroxide (TBAH) into the reaction mixture of compound **7** with HA enabled the synthesis of compound **8**, characterized by ¹HNMR data of the conjugate, and verified by Ellman test for detection of free thiol group²⁴ as well as ninhydrin test for free amino group after removal of protecting groups on the Cys moiety. Finally, Cys-HA conjugate **9** was obtained by cleavage of Boc protecting group of compound **8** with TFA, and followed by treatment with ethanol/H₂O (1:1) to free the Cys, monitored by ¹HNMR analysis and Ellman test.

 Measurement of the thiol content and the degree of modification (DS, HA disaccharide unit %), indicated that the DS was up to 3.3%. The modification sites on HA were proposed to be 6-position as illustrated, based on the hydroxyl group at 6-position being a primary alcohol and much less sterically and spatially hindered than the secondary alcohols at the $2-$ and $3-$ positions.²⁵ The molecular weight (Mw) of Cys-HA conjugate **9** was determined by gel permeation chromatography (GPC) to be 132kDa (ESI), indicating that the molecular weight was only minimally reduced compared to the HA starting material (143kDa) during the chemical modifications shown in Scheme 1.

 To confirm the functionality of modified Cys-HA conjugate **9** and its potential application for *in situ* hydrogel formation, we explored preparation of hydrogels of **9** cross-linked by native chemical ligation (NCL),^{21a} and Michael addition²⁶ under mild conditions using this HA conjugate. In the case of NCL, a thioester can react with an *N*terminal-Cys to form a new amide bond under mild conditions (Scheme 2).²⁷ Advantages of NCL include chemoselectivity (only an *N*terminal-Cys is reactive), high efficiency, mild aqueous reaction conditions, and regeneration of free thiol side chain of the *N*-terminal Cys. NCL has been used to form covalently cross-linked hydrogels,^{21a} allowing further biofunctionalization of the hydrogel network with bioactive compounds for tailoring the biological properties of *in situ* formed hydrogels.^{21d}

Scheme 2. Chemistry of native chemical ligation (NCL).

 We found that mixing aqueous solutions of Cys-HA conjugate **9** and poly(ethylene glycol) (PEG) thioester **10** resulted in hydrogel formation (Scheme 3). Gel formation time could be significantly affected by buffer pH, conjugate concentration, polymer architecture, reactant stoichiometry, and reaction temperature. Control

experiments with 20 mM tricarboxyethylphosphine (TCEP) in water to reduce intermolecular disulfide bonds, and with 100 mM 2 mercaptoethanol (MCE) to cleave the disulfide bonds and thioester bond by thiol exchange in water, were performed to confirm the formation of amide cross-linked HA-PEG hydrogels. The persistence of hydrogels formed from Cys-HA conjugate **9** and PEG thioester **10** in the presence of TCEP and MCE confirmed that the gels formed mainly by cross-linking through NCL rather than intermolecular disulfide of Cys-HA conjugate, or thioester exchange.

Scheme 3. The hydrogel formed by Cys-HA conjugate **9** and 4-arm-PEG-EMP thioester **10** by native chemical ligation.

 Furthermore, the hydrogel formation process and viscoelastic behavior of the hydrogels formed by NCL of Cys-HA conjugate 9 and PEG thioester 10, were investigated by oscillatory rheology using optimized conditions for measurement of a G'/G" crossover point.28 The time-dependent changes in storage modulus (G') and loss modulus (G") for the hydrogel composition tested were characteristic of elastic hydrogel formation (Fig. 1), as indicated by a low initial G' (G' < G"), and a G'/G" crossover point representing a theoretical gelling point, followed by rapid increase in G' to a plateau value. Subsequent frequency and strain sweep experiments conducted after G' reached a plateau indicated the storage modulus was frequency and strain independent as expected for a covalently cross-linked hydrogel.²⁹

 To illustrate the versatile nature of Cys-HA conjugate 9, hydrogels cross-linked by Michael addition26 were prepared under mild conditions by mixing Cys-HA conjugate 9 and 4-armed PEG-acrylate (ACLT) conjugate. It was found that hydrogels formed by Michael addition of Cys-HA conjugate 9 and 4-armed PEG-ACLT conjugate reached the gelling point more rapidly (Fig. 2) compared to those formed by NCL under the same conditions (8 min vs 20 min).

 In summary, we developed a new strategy for the functionalization of hyaluronic acid by chemical modification of alcohol groups through a stable ether bond to obtain a cysteinehyaluronic acid conjugate. The method preserves the free carboxylic acid of the disaccharide repeat unit of HA, therefore facilitating the use of chemically modified HA in future biomedical applications where interactions between HA and biomolecules (e.g. CD44) may be important. We demonstrated that the Cys-HA conjugate is reactive with the polymers containing thiol-reactive groups and can be used to prepare hydrogels cross-linked by native chemical ligation and Michael addition under mild conditions, respectively. Injectable and in situ formed HA hydrogels could be useful in tissue engineering, tissue repair, and drug delivery in a minimally invasive way. The modified HA conjugate could be used for further bio-functionalization with bioactive molecules and engineering of bioactive surfaces through the thiol and amino groups. The method of HA modification reported here may also be applicable to the modification of other natural polysaccharides.

Fig. 1. Oscillatory rheology of the hydrogel formed by native chemical ligation of Cys-HA conjugate 9 (5% w/v) and 4-armed PEG-EMP thioester 10 (0.5% w/v) in phosphate buffer solution (pH 7.5) at 25°C with the molar ratio of cysteine and thioester 2:1. Storage (G') and Storage (G'') modulus vs time are shown.

Fig. 2. Oscillatory rheology of the hydrogel formed by Michael addition of Cys-HA conjugate 9 (5% w/v) and 4-armed PEG-ACLT conjugate (0.5% w/v) in phosphate buffer solution (pH 7.5) at 25°C with the molar ratio of cysteine and acrylate 2:1. Storage (G') and Storage (G'') modulus vs time are shown.

 This research was supported by the National Natural Science Foundation of China (No. 21074027), Hainan University Starting Grant, and grants from the National Institutes of Health (R01 DE021215 and R01 DE021104).

Notes and references

a Key Laboratory of Tropical Biological Resources of Ministry of Education, College of Oceanography, Hainan University, Haikou, Hainan Province 570228, China. Tel: 86 0898 66289567; E-mail: bhhu@hainu.edu.cn. b Departments of Bioengineering and Materials Science and Engineering, University of California, Berkeley, CA, 94720-1760, USA. Tel: 01 510 643 9631; E-mail: philm@berkeley.edu.

† Electronic Supplementary Information (ESI) available: Detailed experimental procedures, chemical and molecular weight characterization and hydrogel formation, as well as oscillatory rheology of hydrogels. See DOI: 10.1039/c000000x/

- 1 G. Kogan, L. Šoltés, R. Stern and P. Gemeiner, *Biotechnol. Lett.*, 2007, **29**, 17.
- 2 J. Y. Lee and A. P. Spicer, *Curr. Opin. Cell Biol.*, 2000, **12**, 581.
- 3 J. D. A. Carruthers, R. G. Glogau, A. Blitzer and t. F. A. C. G. Faculty, *Plast. Reconstr. Surg.*, 2008, **121**, 31S.
- 4 X. Xu, A. K. Jha, D. A. Harrington, M. C. Farach-Carson and X. Jia, *Soft Matter*, 2012, **8**, 3280.
- 5 J. A. Burdick and G. D. Prestwich, *Adv. Mater.*, 2011, **23**, H41.
- 6 L. W. Moreland, *Arthritis Res. Ther.*, 2003, **5**, 54.
- 7 (a) J. L. Young and A. J. Engler, *Biomaterials*, 2011, **32**, 1002; (b) S. Khetan, M. Guvendiren, W. R. Legant, D. M. Cohen, C. S. Chen and J. A. Burdick, *Nat Mater*, 2013, **12**, 458; (c) M. Guvendiren and J. A. Burdick, *Curr. Opin. Biotechnol.*, 2013, **24**, 841.
- 8 M. R. Jackson, *Nat. Med.*, 1996, **2**, 637.
- 9 J. Kablik, G. D. Monheit, L. Yu, G. Chang and J. Gershkovich, *Dermatol. Surg.*, 2009, **35**, 302.
- 10 E. A. Balazs, *Curr. Pharm. Biotechnol.*, 2008, **9**, 236.
- 11 M. Morra, *Biomacromolecules*, 2005, **6**, 1205.
- 12 (a) J.-H. Kong, E. J. Oh, S. Y. Chae, K. C. Lee and S. K. Hahn, *Biomaterials*, 2010, **31**, 4121; (b) Y. Luo, M. R. Ziebell and G. D. Prestwich, *Biomacromolecules*, 2000, **1**, 208.
- 13 (a) N. A. Peppas, J. Z. Hilt, A. Khademhosseini and R. Langer, *Adv. Mater.*, 2006, **18**, 1345; (b) K. Y. Lee and D. J. Mooney, *Chem. Rev.*, 2001, **101**, 1869.
- 14 X. Zheng Shu, Y. Liu, F. S. Palumbo, Y. Luo and G. D. Prestwich, *Biomaterials*, 2004, **25**, 1339.
- 15 (a) C. E. Schante, G. Zuber, C. Herlin and T. F. Vandamme, *Carbohydr. Polym.*, 2011, **85**, 469; (b) P. Bulpitt and D. Aeschlimann, *J. Biomed. Mater. Res.*, 1999, **47**, 152; (c) A. Darr and A. Calabro, *J. Mater. Sci. Mater. Med.*, 2009, **20**, 33; (d) X. Z. Shu, Y. Liu, Y. Luo, M. C. Roberts and G. D. Prestwich, *Biomacromolecules*, 2002, **3**, 1304.
- 16 T. Pouyani, J. W. Kuo, G. S. Harbison and G. D. Prestwich, *J. Am. Chem. Soc.*, 1992, **114**, 5972.
- 17 L. E. Davis, Roth, S.A., Anderson, B., *Immunology*, 1984, **53**, 435.
- 18 (a) V. B. Lokeshwar and M. G. Selzer, *J. Biol. Chem.*, 2000, **275**, 27641; (b) R. Tammi, D. MacCallum, V. C. Hascall, J.-P. Pienimäki, M. Hyttinen and M. Tammi, *J. Biol. Chem.*, 1998, **273**, 28878.
- 19 X. Jia, J. A. Burdick, J. Kobler, R. J. Clifton, J. J. Rosowski, S. M. Zeitels and R. Langer, *Macromolecules*, 2004, **37**, 3239.
- 20 M. A. Serban, G. Yang and G. D. Prestwich, *Biomaterials*, 2008, **29**, 1388.
- 21 (a) B.-H. Hu, J. Su and P. B. Messersmith, *Biomacromolecules*, 2009, **10**, 2194; (b) J. P. Jung, A. J. Sprangers, J. R. Byce, J. Su, J. M. Squirrell, P. B. Messersmith, K. W. Eliceiri and B. M. Ogle, *Biomacromolecules*, 2013, **14**, 3102; (c) I. Strehin, D. Gourevitch, Y. Zhang, E. Heber-Katz and P. B. Messersmith, *Biomater. Sci.*, 2013, **1**, 603; (d) J. Su, B.-H. Hu, W. L. Lowe Jr, D. B. Kaufman and P. B. Messersmith, *Biomaterials*, 2010, **31**, 308.
- 22 D. S. Kemp and R. I. Carey, *J. Org. Chem.*, 1989, **54**, 3640.
- 23 A. F. Wagner, E. Walton, G. E. Boxer, M. P. Pruss, F. W. Holly and K. Folkers, *J. Am. Chem. Soc.*, 1956, **78**, 5079.
- 24 G. L. Ellman, *Arch. Biochem. Biophy.*, 1959, **82**, 70.
- 25 C. K. Lee, E. J. Kim and J. H. Jun, *Bull. Korean Chem. Soc.*, 1999, **20**, 1153.
- 26 M. P. Lutolf, N. Tirelli, S. Cerritelli, L. Cavalli and J. A. Hubbell, *Bioconjugate Chem.*, 2001, **12**, 1051.
- 27 T. Wieland, E. Bokelmann, L. Bauer, H. U. Lang, H. Lau and W. Schafer, *Liebigs. Ann. Chem.*, 1953, **583**, 129.
- 28 G. M. Kavanagh and S. B. Ross-Murphy, *Prog. Polym. Sci.*, 1998, **23**, 533.
- 29 S. B. Ross-Murphy, *Polym. Gels Netw.*, 1994, **2**, 229.